Cryoport's second quarter of 2026 demonstrated robust financial health, with notable increases in total revenue and a significant stride towards profitability through positive adjusted EBITDA. The company showcased strong performance across its Life Science Services segment, particularly in biostorage and cell and gene therapy support. Strategic initiatives, including global supply chain expansion and the integration of artificial intelligence, underscore Cryoport's commitment to innovation and market leadership. Despite global uncertainties, the company maintained its full-year revenue guidance, reflecting confidence in its operational plans and market position. The focus on scaling operations and enhancing efficiency positions Cryoport for sustained long-term growth in the rapidly evolving life sciences sector.
Cryoport's continued advancement in the cell and gene therapy sector is evident in its second-quarter 2026 results. The company reported a total revenue of $49 million, an 8% growth, predominantly fueled by its Life Science Services division. This segment saw a 15% year-over-year increase, with BioStorage/BioServices revenue surging by 25% due to high demand for integrated services. Commercial Cell and Gene Therapy (CGT) revenue grew 9% to $9.4 million, with service components experiencing a 26% rise as patient treatments shifted towards community and outpatient settings. Clinical trial support also expanded by 12% to $13.4 million, reflecting the maturation of client pipelines. Importantly, Cryoport achieved positive adjusted EBITDA of $375,000, a $1.3 million improvement from the previous year, marking a critical milestone in its journey toward profitability. The company ended the quarter with $396.7 million in cash and short-term investments, providing substantial liquidity for ongoing strategic endeavors.
Advancing Global Logistics and Innovation in Life Sciences
Cryoport is strategically enhancing its global supply chain and embracing technological advancements to fortify its position in the life sciences logistics market. The company's expansion plans include launching new BioServices operations in Paris, France, and a global supply chain center in Santa Ana, California, during the fourth quarter. These state-of-the-art facilities are designed to significantly bolster Cryoport's capacity to deliver sophisticated temperature-controlled supply chain solutions worldwide. Furthermore, Cryoport is at the forefront of integrating generative AI and machine learning into its operations. These tools are being leveraged to automate routine tasks, analyze vast datasets, mitigate risks, and accelerate decision-making processes, all while maintaining human oversight. This technological adoption not only boosts productivity but also reinforces the company's enterprise technology strategy, providing employees with innovative tools for continuous improvement.
Cryoport's dedication to innovation extends to its product offerings and global footprint. The MVE Fusion 811 self-regenerating cryogenic freezer, which operates without liquid nitrogen refills, is expected to democratize access to cell and gene therapies for community care hospitals. This product, alongside the commencement of cryogenic freezer production in Chengdu, China, highlights Cryoport's efforts to reduce tariffs, enhance competitive positioning, and cater to regional demands. The company's IntegriCell cryopreservation services are also gaining traction, with clinical processes now established in Houston, Texas, and Liège, Belgium. The selection of IntegriCell by Verismo Therapeutics for its KIR-CAR T-cell therapy programs underscores the service's potential to standardize and scale the cell therapy industry. Cryoport's strategic focus on expanding its network, developing smart products, and harnessing AI technologies is poised to drive sustainable, profitable growth and reinforce its leadership in providing critical temperature-controlled supply chain solutions globally.
